Complement C3 is downregulated following ranibizumab intervention in experimental central retinal vein occlusion.

ABSTRACT:

Purpose

Ranibizumab is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the treatment of macular edema following central retinal vein occlusion (CRVO). Studying proteins that mediate the beneficial effects of ranibizumab in CRVO can potentially lead to the improved management of macular edema.

Methods

In 14 Danish Landrace pigs, experimental CRVO was induced in the right eyes and treated with either intravitreal ranibizumab (n = 6) or an intravitreal sodium chloride 9 mg/mL solution as a sham injection (n = 8). Successful CRVO was confirmed by fluorescein angiography. Retinal samples were collected 15 days after induced CRVO and analyzed with label-free, quantification, nano-liquid chromatography-tandem mass spectrometry. Validation was performed w

SUBMITTER: Cehofski LJ 

PROVIDER: S-EPMC11575839 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature